TY - JOUR
T1 - Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation
T2 - Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
AU - ORBIT-AF Investigators
AU - Gundlund, Anna
AU - Fosbøl, Emil Loldrup
AU - Kim, Sunghee
AU - Fonarow, Gregg C.
AU - Gersh, Bernard J.
AU - Kowey, Peter R.
AU - Hylek, Elaine
AU - Mahaffey, Kenneth W.
AU - Thomas, Laine
AU - Piccini, Jonathan P.
AU - Peterson, Eric D.
N1 - Funding Information:
Ms Gundlund has no conflicts of interest. Dr Fosbol has no conflicts of interest. Ms Kim has no conflicts of interest. Dr Fonarow has received consultancy fees from Janssen Pharmaceuticals. Dr Gersh has been a consultant to Medtronic and Johnson & Johnson. Dr Kowey has been a consultant to Johnson & Johnson. Dr Hylek has received honoraria from Bayer, Boehringer Ingelheim, and Bristol Myers Squibb, and has been in the advisory board for Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Medtronic, and Pfizer. Kenneth W. Mahaffey's financial disclosures prior to August 1, 2013, can be viewed at https://www.dcri.org/about-us/conflict-of-interest/Mahaffey-COI_2011-2013.pdf ; disclosures after August 1, 2013, can be viewed at http://med.stanford.edu/profiles/kenneth_mahaffey . Ms Thomas has no conflicts of interest. Dr. Piccini has received consultant fees or honoraria from Johnson & Johnson, Medtronic, and Spectranetics and research grants from Arca Biopharma, Boston Scientific, GE healthcare, Johnson & Johnson, and Resmed. Dr. Peterson has received consultant fees or honoraria from Astra Zenecca, Boehringer Ingelheim, and Janssen and research grants from Astra Zenecca, Eli Lilly, Janssen, Genentech, and Sanofi. All authors have approved the final version of the manuscript.
Publisher Copyright:
© 2016 The Authors.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background We addressed whether patients with a family history of atrial fibrillation (AF) were diagnosed as having AF earlier in life, were more symptomatic, and had worse outcomes compared with those without a family history of AF. Methods Using the ORBIT-AF, we compared symptoms and disease characteristics in those with and without a family history of AF. A family history of AF was defined as AF in a first-degree family member and obtained by patient self-reporting. Multivariable Cox proportional hazard analyses were performed to compare the incidence of cardiovascular outcomes, AF progression, all-cause hospitalization, and all-cause death. Results Among 9,999 patients with AF from 176 US outpatient clinics, 1,481 (14.8%) had a family history of AF. Relative to those without, those with a family history of AF developed AF 5 years earlier on average (median age 65 vs 70 years, P <.01), with less comorbidity, and had more severe AF-related symptoms. No differences were found between the 2 groups in the risk of AF progression (adjusted hazard ratio [HR] 0.98, 95% CI 0.85-1.14), stroke, non-central nervous system embolism, or transient ischemic attack (adjusted HR 0.95, 95% CI 0.67-1.34), all-cause hospitalization (adjusted HR 1.03, 95% CI 0.94-1.12), and all-cause death (adjusted HR 1.05, 95% CI 0.86-1.27). Conclusions Patients with a family history of AF developed AF at a younger age, had less comorbidity, and were more symptomatic. Once AF developed, no significantly increased risks of AF progression and thromboembolism were associated with a family history of AF compared with no family history.
AB - Background We addressed whether patients with a family history of atrial fibrillation (AF) were diagnosed as having AF earlier in life, were more symptomatic, and had worse outcomes compared with those without a family history of AF. Methods Using the ORBIT-AF, we compared symptoms and disease characteristics in those with and without a family history of AF. A family history of AF was defined as AF in a first-degree family member and obtained by patient self-reporting. Multivariable Cox proportional hazard analyses were performed to compare the incidence of cardiovascular outcomes, AF progression, all-cause hospitalization, and all-cause death. Results Among 9,999 patients with AF from 176 US outpatient clinics, 1,481 (14.8%) had a family history of AF. Relative to those without, those with a family history of AF developed AF 5 years earlier on average (median age 65 vs 70 years, P <.01), with less comorbidity, and had more severe AF-related symptoms. No differences were found between the 2 groups in the risk of AF progression (adjusted hazard ratio [HR] 0.98, 95% CI 0.85-1.14), stroke, non-central nervous system embolism, or transient ischemic attack (adjusted HR 0.95, 95% CI 0.67-1.34), all-cause hospitalization (adjusted HR 1.03, 95% CI 0.94-1.12), and all-cause death (adjusted HR 1.05, 95% CI 0.86-1.27). Conclusions Patients with a family history of AF developed AF at a younger age, had less comorbidity, and were more symptomatic. Once AF developed, no significantly increased risks of AF progression and thromboembolism were associated with a family history of AF compared with no family history.
UR - http://www.scopus.com/inward/record.url?scp=84960125684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960125684&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2016.01.020
DO - 10.1016/j.ahj.2016.01.020
M3 - Article
C2 - 27179721
AN - SCOPUS:84960125684
SN - 0002-8703
VL - 175
SP - 28
EP - 35
JO - American Heart Journal
JF - American Heart Journal
ER -